


Healthcare Industry News: HIV/AIDS
News Release - July 20, 2017
Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD)
Source: Theravance Biopharma
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
